ProfileGDS5678 / 1428313_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 32% 39% 31% 34% 50% 32% 31% 31% 30% 33% 35% 33% 33% 33% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7511732
GSM967853U87-EV human glioblastoma xenograft - Control 22.8982239
GSM967854U87-EV human glioblastoma xenograft - Control 32.715931
GSM967855U87-EV human glioblastoma xenograft - Control 42.7087534
GSM967856U87-EV human glioblastoma xenograft - Control 53.1634950
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7985232
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7476431
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6840931
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6664130
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7405933
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7985235
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7288333
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7531633
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7387933